Literature DB >> 22182450

Synergistic interaction between cisplatin and gemcitabine in neuroblastoma cell lines and multicellular tumor spheroids.

Odette G Besançon1, Godelieve A M Tytgat, Rutger Meinsma, René Leen, Jerry Hoebink, Ganna V Kalayda, Ulrich Jaehde, Huib N Caron, André B P van Kuilenburg.   

Abstract

The efficacy and mechanism of action of cisplatin and gemcitabine were investigated in a panel of neuroblastoma cell lines and multicellular tumor spheroids. In neuroblastoma spheroids, the combination of cisplatin and gemcitabine induced a complete cytostasis at clinical relevant concentrations. A synergistic effect was observed when cells were coincubated with both drugs or preincubated with gemcitabine first. These administration sequences resulted in NASS cells in decreased ERCC1 and XPA expression, two key proteins of the NER DNA repair system, and increased platinum adduct formation in DNA. Most of these phenomena were not observed in SJNB8 cells which might explain the lack of synergy between cisplatin and gemcitabine in SJNB8 cells. Our results showed favorable interactions between cisplatin and gemcitabine in 4 out of 5 cell lines. Therefore, we feel that inclusion of gemcitabine into cisplatin-containing regiments might be a promising new strategy for the treatment of neuroblastoma.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22182450     DOI: 10.1016/j.canlet.2011.12.016

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  10 in total

1.  Nanoparticles with Precise Ratiometric Co-Loading and Co-Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer.

Authors:  Lei Miao; Shutao Guo; Jing Zhang; William Y Kim; Leaf Huang
Journal:  Adv Funct Mater       Date:  2014-11-12       Impact factor: 18.808

2.  Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model.

Authors:  Jing Zhang; Lei Miao; Shutao Guo; Yuan Zhang; Lu Zhang; Andrew Satterlee; William Y Kim; Leaf Huang
Journal:  J Control Release       Date:  2014-03-15       Impact factor: 9.776

Review 3.  Nanoformulations for combination or cascade anticancer therapy.

Authors:  Lei Miao; Shutao Guo; C Michael Lin; Qi Liu; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2017-06-15       Impact factor: 15.470

4.  A SPATIOTEMPORAL MODEL TO SIMULATE CHEMOTHERAPY REGIMENS FOR HETEROGENEOUS BLADDER CANCER METASTASES TO THE LUNG.

Authors:  Kimberly R Kanigel Winner; James C Costello
Journal:  Pac Symp Biocomput       Date:  2017

5.  Advanced Nanoengineering Approach for Target-Specific, Spatiotemporal, and Ratiometric Delivery of Gemcitabine-Cisplatin Combination for Improved Therapeutic Outcome in Pancreatic Cancer.

Authors:  Mubin Tarannum; Md Akram Hossain; Bryce Holmes; Shan Yan; Pinku Mukherjee; Juan L Vivero-Escoto
Journal:  Small       Date:  2021-11-10       Impact factor: 13.281

6.  Cell-Laden Hydrogel as a Clinical-Relevant 3D Model for Analyzing Neuroblastoma Growth, Immunophenotype, and Susceptibility to Therapies.

Authors:  Alessandra Marrella; Alessandra Dondero; Maurizio Aiello; Beatrice Casu; Daniel Olive; Stefano Regis; Cristina Bottino; Daniela Pende; Raffaella Meazza; Guido Caluori; Roberta Castriconi; Silvia Scaglione
Journal:  Front Immunol       Date:  2019-08-09       Impact factor: 7.561

7.  Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines.

Authors:  Yasunari Sakamoto; Seri Yamagishi; Takuji Okusaka; Hidenori Ojima
Journal:  Cells       Date:  2019-09-03       Impact factor: 6.600

8.  A Simple Three-Dimensional In Vitro Culture Mimicking the In Vivo-Like Cell Behavior of Bladder Patient-Derived Xenograft Models.

Authors:  Robson Amaral; Maike Zimmermann; Ai-Hong Ma; Hongyong Zhang; Kamilla Swiech; Chong-Xian Pan
Journal:  Cancers (Basel)       Date:  2020-05-21       Impact factor: 6.639

9.  Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients.

Authors:  Yuanyuan Sun; Ling Li; Xin Li; Lei Zhang; Xinhua Wang; Xiaorui Fu; Zhenchang Sun; Xudong Zhang; Zhaoming Li; Jingjing Wu; Hui Yu; Yu Chang; Jiaqin Yan; Xiaolong Wu; Zhiyuan Zhou; Feifei Nan; Li Tian; Mingzhi Zhang
Journal:  Ther Adv Med Oncol       Date:  2020-05-27       Impact factor: 8.168

10.  GX15-070 (Obatoclax), a Bcl-2 family proteins inhibitor engenders apoptosis and pro-survival autophagy and increases Chemosensitivity in neuroblastoma.

Authors:  Sonia Cournoyer; Anissa Addioui; Assila Belounis; Mona Beaunoyer; Carine Nyalendo; Roxane Le Gall; Pierre Teira; Elie Haddad; Gilles Vassal; Hervé Sartelet
Journal:  BMC Cancer       Date:  2019-10-29       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.